Integrative Molecular Analyses of Inflammatory and Autoimmune Signals in Cardiac Sarcoidosis
Meraj Neyazi1,2,3, Gabriela Venturini1, Kemar J Brown1,4
1Department of Genetics (M.N., G.V., K.J.B., Y.C., J.M.G., O.G.L., A. Verma, A.J.W., B.A.M., D.M.D., S.R.D., D.R., H.W., S.J.E., J.G.S., C.E.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Insights
Cardiac sarcoidosis (CS) involves immune cells creating autoantibodies against cardiac cells, like PPL. This discovery offers new therapeutic targets for CS and related heart conditions.
Area of Science:
- Cardiovascular Pathology
- Immunology
- Genomics
Background:
- Cardiac sarcoidosis (CS) is a poorly understood condition causing inflammation, arrhythmias, and heart failure.
- The precise mechanisms behind CS histopathology and disease progression remain unclear.
Purpose of the Study:
- To investigate the cellular and molecular landscape of human CS hearts across different pathological regions.
- To identify the specific targets of autoimmune responses in CS.
Main Methods:
- Comprehensive single-cell and spatial transcriptomic analyses were performed on CS heart tissues.
- Antibodies from clonally expanded B cells were reconstructed and screened against various peptide libraries.
- Epitope mapping was used to identify autoantigens reactive in CS.
Main Results:
- Distinct cellular compositions and gene expression patterns were observed in preserved, granulomatous, and fibrotic CS regions.
- Cardiomyocytes and fibroblasts secreted chemoattractants, while macrophages modulated cell fusion and T cells promoted B-cell activation.
- Antibodies from CS patients reacted to periplakin (PPL), a desmosome protein, and other cardiac cell-expressed peptides.
Conclusions:
- CS involves an intracardiac humoral autoimmune axis, with patient-specific antibodies targeting cardiac proteins like PPL.
- PPL identification links CS to arrhythmic desmosomal cardiomyopathies and suggests shared pathogenic mechanisms.
- Targeting granuloma formation and B-cell activation presents therapeutic opportunities for CS and related cardiac immune disorders.
Background:
Cardiac sarcoidosis (CS) is an enigmatic disorder characterized by unexplained patchy, sterile granulomas intermixed with preserved myocardium and fibrotic regions without granuloma. CS causes arrhythmias, sudden cardiac death, and heart failure. The mechanisms producing this remarkable histopathology and disease progression remain unexplained.
Methods:
Using comprehensive single-cell and spatial transcriptomic analyses, we characterized the cellular composition and gene expression in preserved, granulomatous, and fibrotic regions of human CS hearts. From unexpectedly identified clonally expanded cardiac B cells with rearranged immunoglobulin sequences, we reconstructed antibodies and screened libraries comprising the human peptidome or microbial and allergen peptides to define reactive epitopes in CS hearts.
Results:
Cellular composition and gene expression differed substantially in CS tissues with preserved, granulomatous, or fibrotic histopathology. Cardiomyocytes upregulated arrhythmogenic and inflammasome transcripts associated with pyroptosis. Cardiomyocytes and fibroblasts activated chemoattractant cytokines that sustained myeloid and lymphoid infiltration. Granulomas contained abundant macrophages expressing modulators of cell-cell fusion, along with Th17-skewed T cells that upregulated B-cell-activating factor, thereby promoting antibody production. Fibrotic regions, without active granulomas, exhibited tertiary lymphoid structures, with clonal expansion of mature B and plasma cells. Reconstructed antibodies derived from expanded B-cell clones were inert to microbial and allergen peptides, but reacted to PPL (periplakin), a desmosome protein, and other peptides expressed on cardiac cells.
Conclusions:
Progressive inflammatory signals in CS are mediated by chemoattractant genes in cardiomyocytes and fibroblasts within preserved myocardium, cell-cell fusion modulators in activated macrophages within granulomatous regions, and tertiary lymphoid structures in fibrotic regions that produce patient-specific autoimmune antibodies. Identification of PPL as a CS autoantigen may account for shared clinical manifestations in CS and arrhythmic desmosomal cardiomyopathies. CS autoantigens may underlie enigmatic histopathologic findings, perpetuate disease, and contribute to adverse outcomes. Uncovering an intracardiac humoral autoimmune axis in CS provides specific therapeutic opportunities to limit granuloma formation and B-cell activation, which may reduce arrhythmogenicity and progressive dysfunction. Parallel analytic strategies have potential to define autoantigens in other enigmatic cardiac immune disorders.
Related Concept Videos
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The JAK-STAT Signaling Pathway
Cardiomyopathy IV: Restrictive Cardiomyopathy
